Pancreatic cancer: State of the Art
Celgene planned the launch of Abraxane® for the treatment of pancreatic cancer. Abraxane® contains an albumin-bound formulation of paclitaxel that enables a higher concentration of the active ingredient in tumor tissue. These interesting scientific facts should be spread to the oncological community.
Together with a renowned opinion leader in oncology, our experienced medical writers identified the relevant content and wrote an extensive state-of-the-art review in English.
The publication in the internationally renowned journal “Cancer Treatment Reviews” was well received: Within 6 months the article was already cited 11 times – a very good value for a review and an important contribution to communicating the therapeutic progress with Abraxane®.